RenovoRx, a biotech company headquartered in Silicon Valley, California, has developed a therapy platform to deliver chemotherapy, to difficult-to-treat tumors. Targeted therapy via the proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP) platform safely and without transmission to non-targeted areas, is the primary focus. RenovoRx’s patent portfolio currently includes six issued US patents and one European patent for its technology with several additional patents pending in the US, Europe, and Asia.
After demonstrating a median survival of 27.9 months in Phase I/II clinical trials vs. 12-15 months reported in historical studies for this patient population, RenovoRx secured two separate Orphan Drug Designations from the FDA for intra-arterial gemcitabine: pancreatic cancer and bile duct cancer (cholangiocarcinoma). This therapy is being further studied in the currently enrolling Phase III TIGeR-PaC trial evaluating extended median overall survival and improved quality of life for pancreatic cancer patients.
The randomized TIGeR-PaC trial is enrolling unresectable locally advanced pancreatic cancer patients in the United States and Europe.